Should I Buy JAZZ? JAZZ 2026 Analysis

Should You Buy Jazz Pharmaceuticals PLC (JAZZ) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

165.500

1 Day change

1.44%

52 Week Range

182.990

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: Price is sitting just below the key pivot (~~167) and above first support (~~163.6), offering a reasonable entry without needing to wait for an “optimal” pullback.
Sentiment supports upside: Options positioning is call-leaning (low put/call OI) and implied volatility is relatively low, which often aligns with calmer/bullish expectations.
Wall Street is broadly constructive: Multiple recent price target raises into 2026 with consistent Buy/Overweight ratings; upside to consensus targets remains meaningful.
Fundamentals are working: Latest reported quarter (2025/Q3) showed solid revenue/EPS growth, supporting the bull case going into the next earnings (2026-02-26).
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Slightly bearish-to-neutral near-term—MACD histogram is negative (-0.344) but negatively contracting, suggesting downside momentum is fading.
RSI: RSI(6) ~44.7 = neutral, not oversold; no strong reversal signal yet.
Moving averages: Converging MAs imply consolidation/range behavior rather than a strong trend.
Key levels:
- Pivot: 167.05 (pre-market ~166.41 is just below)
- Support: 163.60 (S1) then 161.47 (S2)
- Resistance: 170.49 (R1) then 172.62 (R2)
Interpretation: Technically this looks like a base/consolidation; a push back above ~167 improving toward ~170.5 would confirm strengthening, but current setup is already close enough to support to justify an impatient entry.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/Call open interest ratio 0.43 = call-heavy/open-interest skew that leans bullish.
Flow: Put/Call volume ratio 0.75 = slightly more calls than puts (mildly bullish), though absolute volume is small.
Volatility: 30D IV ~33.8% vs historical vol 29.8% (modestly higher), but IV percentile ~23.9 and IV rank ~4.9 suggest IV is low relative to its own history (less fear / cheaper optionality).
Activity vs normal: Today’s option volume vs 30D average is 1.44x, indicating a small pickup in attention.

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst upgrades/target raises tied to zanidatamab (Ziihera) data: Multiple firms raised targets after Phase 3 HERIZON-GEA-01 updates; some see $1B–$2B+ peak sales potential with broader HER2 opportunity.
- Upcoming earnings: QDEC 2025 earnings on 2026-02-26 (after hours) is the nearest scheduled catalyst.
- Pipeline momentum narrative: Continued shift toward a more oncology-focused growth profile (zanidatamab read-through potential into additional indications noted by analysts).

Neutral/Negative Catalysts

- Near-term technical posture is not strongly bullish: MACD remains below zero and moving averages are converged (more “range” than “breakout”).
- Catalyst cadence risk: UBS flagged limited near-term catalysts after the big move and called the stock closer to fair value.
- No fresh news this week: Lacks an immediate event-driven spark pre-market.
- Influential/political trading: No recent congress trading data available; hedge funds/insiders flagged as neutral (no strong incremental signal).

Financial Performance

Latest quarter: 2025/Q3
- Revenue: $1.126B, +6.74% YoY (steady top-line growth)
- Net income: $251.4M, +16.91% YoY (profit growth outpacing revenue)
- EPS: 4.08, +19.30% YoY (strong earnings leverage)
- Gross margin: 73.6%, -1.21% YoY (minor margin compression, but still high for the business)
Takeaway: Growth trend is positive and supports a constructive stance into the next earnings cycle.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent direction: Predominantly price target increases and reaffirmed Buy/Overweight ratings through late 2025 into early 2026.
Notable bullish updates:
- BofA raised PT to $263 (Buy) citing confidence in zanidatamab approval odds/peak sales.
- TD Cowen raised PT to $220 (Buy); Morgan Stanley to $225 (Overweight); Piper to $219 (Overweight); Wells Fargo to $235 (Overweight).
Key dissent:
- UBS downgraded to Neutral with PT $188, arguing the post-data rally left a more balanced risk/reward.
Wall Street pros/cons view:
- Pros: Strong oncology pipeline momentum (zanidatamab) + improving long-term growth profile.
- Cons: After the prior run, some see valuation as closer to fair and near-term upside more catalyst-dependent.

13 Analyst Rating

Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188 USD and a high forecast of 263 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

1 Hold

0 Sell

Strong Buy

Current: 163.150

Low

188

Averages

218.92

High

263

Current: 163.150

Low

188

Averages

218.92

High

263

TD Cowen

Joseph Thome

Buy

maintain

$205 -> $220

AI Analysis

2026-01-29

Reason

TD Cowen

Joseph Thome

Price Target

$205 -> $220

AI Analysis

2026-01-29

maintain

Buy

Reason

TD Cowen analyst Joseph Thome raised the firm's price target on Jazz Pharmaceuticals to $220 from $205 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.

BofA

Buy

maintain

$247 -> $263

2026-01-09

Reason

BofA

Price Target

$247 -> $263

2026-01-09

maintain

Buy

Reason

BofA raised the firm's price target on Jazz Pharmaceuticals to $263 from $247 and keeps a Buy rating on the shares following the detailed presentation of Phase 3 HERIZON-GEA-01 data at ASCO GI. Shares were under pressure after the presentation, but the firm thinks the selloff was "unwarranted" as the presentation did not yield any material findings to change the drug's approval prospects or peak sales outlook, the analyst tells investors. The firm thinks the full data look good and support a $1B peak sales forecast for Ziihera in first-line gastroesophageal adenocarcinoma, adds the analyst, who increased the view of program's odds of success to 85% from 63%.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JAZZ

Unlock Now

JAZZ Should I Buy

JAZZ Should I Buy

Should You Buy Jazz Pharmaceuticals PLC (JAZZ) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch